A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo

Ashwani Rajput, Alan P. Koterba, Jeffrey L. Kreisberg, Jason M Foster, James K.V. Willson, Michael G Brattain

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) is widely expressed in a number of solid tumors including colorectal cancers. Overexpression of this receptor is one means by which a cell can achieve positive signals for survival and proliferation; another effective means is by constitutive activation of EGFR. We have elucidated the role of constitutive EGFR signaling in malignant progression by stably transfecting colon cancer cells with a human transforming growth factor-α cDNA (a ligand for EGFR) under repressible control by tetracycline. We show that constitutive expression of transforming growth factor-α and its subsequent constitutive activation of EGFR allows for cancer cell survival in response to environmental stress in vitro and in vivo as well. The reversal of constitutive EGFR activation results in the loss of downstream mitogen-activated protein kinase and Akt activation, and a reduction in xenograft size that is associated with decreased proliferation and increased apoptosis. We used CI-1033, a small molecule antagonist of EGFR, to dissect an activation pathway that shows the ability of ERBb2 to activate Akt, but not Erk in the face of EGFR antagonism. This novel escape mechanism is a possible explanation of why anti-EGFR therapies have shown disappointing results in clinical trials.

Original languageEnglish (US)
Pages (from-to)665-673
Number of pages9
JournalCancer Research
Volume67
Issue number2
DOIs
StatePublished - Jan 15 2007

Fingerprint

Epidermal Growth Factor Receptor
Transforming Growth Factors
Mitogen-Activated Protein Kinases
Tetracycline
Heterografts
Colonic Neoplasms
Colorectal Neoplasms
Neoplasms
Cell Survival
Complementary DNA
Clinical Trials
Apoptosis
Ligands
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rajput, A., Koterba, A. P., Kreisberg, J. L., Foster, J. M., Willson, J. K. V., & Brattain, M. G. (2007). A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Research, 67(2), 665-673. https://doi.org/10.1158/0008-5472.CAN-06-2773

A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. / Rajput, Ashwani; Koterba, Alan P.; Kreisberg, Jeffrey L.; Foster, Jason M; Willson, James K.V.; Brattain, Michael G.

In: Cancer Research, Vol. 67, No. 2, 15.01.2007, p. 665-673.

Research output: Contribution to journalArticle

Rajput, A, Koterba, AP, Kreisberg, JL, Foster, JM, Willson, JKV & Brattain, MG 2007, 'A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo', Cancer Research, vol. 67, no. 2, pp. 665-673. https://doi.org/10.1158/0008-5472.CAN-06-2773
Rajput, Ashwani ; Koterba, Alan P. ; Kreisberg, Jeffrey L. ; Foster, Jason M ; Willson, James K.V. ; Brattain, Michael G. / A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. In: Cancer Research. 2007 ; Vol. 67, No. 2. pp. 665-673.
@article{d0bb5f5ae2674c9eb65e73aa9c5f65c0,
title = "A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo",
abstract = "Epidermal growth factor receptor (EGFR) is widely expressed in a number of solid tumors including colorectal cancers. Overexpression of this receptor is one means by which a cell can achieve positive signals for survival and proliferation; another effective means is by constitutive activation of EGFR. We have elucidated the role of constitutive EGFR signaling in malignant progression by stably transfecting colon cancer cells with a human transforming growth factor-α cDNA (a ligand for EGFR) under repressible control by tetracycline. We show that constitutive expression of transforming growth factor-α and its subsequent constitutive activation of EGFR allows for cancer cell survival in response to environmental stress in vitro and in vivo as well. The reversal of constitutive EGFR activation results in the loss of downstream mitogen-activated protein kinase and Akt activation, and a reduction in xenograft size that is associated with decreased proliferation and increased apoptosis. We used CI-1033, a small molecule antagonist of EGFR, to dissect an activation pathway that shows the ability of ERBb2 to activate Akt, but not Erk in the face of EGFR antagonism. This novel escape mechanism is a possible explanation of why anti-EGFR therapies have shown disappointing results in clinical trials.",
author = "Ashwani Rajput and Koterba, {Alan P.} and Kreisberg, {Jeffrey L.} and Foster, {Jason M} and Willson, {James K.V.} and Brattain, {Michael G}",
year = "2007",
month = "1",
day = "15",
doi = "10.1158/0008-5472.CAN-06-2773",
language = "English (US)",
volume = "67",
pages = "665--673",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo

AU - Rajput, Ashwani

AU - Koterba, Alan P.

AU - Kreisberg, Jeffrey L.

AU - Foster, Jason M

AU - Willson, James K.V.

AU - Brattain, Michael G

PY - 2007/1/15

Y1 - 2007/1/15

N2 - Epidermal growth factor receptor (EGFR) is widely expressed in a number of solid tumors including colorectal cancers. Overexpression of this receptor is one means by which a cell can achieve positive signals for survival and proliferation; another effective means is by constitutive activation of EGFR. We have elucidated the role of constitutive EGFR signaling in malignant progression by stably transfecting colon cancer cells with a human transforming growth factor-α cDNA (a ligand for EGFR) under repressible control by tetracycline. We show that constitutive expression of transforming growth factor-α and its subsequent constitutive activation of EGFR allows for cancer cell survival in response to environmental stress in vitro and in vivo as well. The reversal of constitutive EGFR activation results in the loss of downstream mitogen-activated protein kinase and Akt activation, and a reduction in xenograft size that is associated with decreased proliferation and increased apoptosis. We used CI-1033, a small molecule antagonist of EGFR, to dissect an activation pathway that shows the ability of ERBb2 to activate Akt, but not Erk in the face of EGFR antagonism. This novel escape mechanism is a possible explanation of why anti-EGFR therapies have shown disappointing results in clinical trials.

AB - Epidermal growth factor receptor (EGFR) is widely expressed in a number of solid tumors including colorectal cancers. Overexpression of this receptor is one means by which a cell can achieve positive signals for survival and proliferation; another effective means is by constitutive activation of EGFR. We have elucidated the role of constitutive EGFR signaling in malignant progression by stably transfecting colon cancer cells with a human transforming growth factor-α cDNA (a ligand for EGFR) under repressible control by tetracycline. We show that constitutive expression of transforming growth factor-α and its subsequent constitutive activation of EGFR allows for cancer cell survival in response to environmental stress in vitro and in vivo as well. The reversal of constitutive EGFR activation results in the loss of downstream mitogen-activated protein kinase and Akt activation, and a reduction in xenograft size that is associated with decreased proliferation and increased apoptosis. We used CI-1033, a small molecule antagonist of EGFR, to dissect an activation pathway that shows the ability of ERBb2 to activate Akt, but not Erk in the face of EGFR antagonism. This novel escape mechanism is a possible explanation of why anti-EGFR therapies have shown disappointing results in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33846696437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846696437&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-2773

DO - 10.1158/0008-5472.CAN-06-2773

M3 - Article

VL - 67

SP - 665

EP - 673

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -